{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:05:31Z","timestamp":1793991931028,"version":"4.8.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":2061,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"vor","delay-in-days":63,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\u2003<\/jats:title>\n                    <jats:p>The purpose of this work was to evaluate systemic glucocorticoid exposure and fracture among patients with newly-diagnosed inflammatory and immune-modulated conditions. Using administrative data, inception cohorts of rheumatoid arthritis (RA), asthma\/chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), multiple sclerosis (MS), lupus, and sarcoidosis patients age 18 to 64 years with benefits coverage \u226512 months before diagnosis (January 1, 2005 to December 31, 2012) were followed to clinical fracture, cancer diagnosis, or December 31, 2012. Glucocorticoid users were new to therapy. Fracture incidence rates (IRs) per 1000 person-years were stratified by prednisone equivalent doses. Cox's proportional hazards models assessed risk by daily and cumulative dose, and by time since discontinuation, adjusted for baseline characteristics. Most patients (72% of 403,337) had glucocorticoid exposure; 52% were under age 50. IR (95% confidence interval [CI]) of any osteoporotic fracture was elevated at doses &amp;lt;5\u2009mg\/day (IR 9.33; 95% CI, 7.29 to 11.77) versus 0\u2009mg\/day (IR 4.87 (95% CI, 4.72 to 5.02). Fracture rates were elevated at doses &amp;lt;5\u2009mg\/day in patients &amp;lt;50 years and those \u226550 years. In both age groups, fracture risk increased with increasing cumulative exposure, being approximately 2.5-fold higher at cumulative dose \u22655400\u2009mg compared to &amp;lt;675\u2009mg. At \u22655400\u2009mg, IR values were 5.69 (95% CI, 4.32 to 7.35) in patients &amp;lt;50 years and 17.10 (95% CI, 14.97 to 19.46) in older patients. Fracture risk decreased significantly within months following glucocorticoid discontinuation. In patients with a variety of inflammatory conditions, fracture risk increased at doses as low as &amp;lt;5\u2009mg\/day. Risk increased with increasing cumulative exposure and decreased soon following glucocorticoid discontinuation. Trends were similar between patients older and younger than 50 years. \u00a9 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jbmr.3523","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T13:11:41Z","timestamp":1529500301000},"page":"1881-1888","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions"],"prefix":"10.1093","volume":"33","author":[{"given":"Akhila","family":"Balasubramanian","sequence":"first","affiliation":[{"name":"Amgen Inc.Thousand Oaks CAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally W","family":"Wade","sequence":"additional","affiliation":[{"name":"Wade Outcomes Research and ConsultingSalt Lake City UTUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Adler","sequence":"additional","affiliation":[{"name":"McGuire Veterans Affairs Medical Center and Virginia Commonwealth UniversityRichmond VAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Saag","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and RheumatologyUniversity of Alabama at BirminghamBirmingham ALUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pannacciulli","sequence":"additional","affiliation":[{"name":"Amgen Inc.Thousand Oaks CAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R","family":"Curtis","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and RheumatologyUniversity of Alabama at BirminghamBirmingham ALUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,20]]},"reference":[{"issue":"2","key":"2024021014300751400_jbmr3523-bib-0001","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/acr.21796","article-title":"Prevalence of oral glucocorticoid usage in the United States: a general population perspective","volume":"65","author":"Overman","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"3","key":"2024021014300751400_jbmr3523-bib-0002","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1359\/JBMR.041125","article-title":"Effects of low-dose prednisone on bone metabolism","volume":"20","author":"Ton","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024021014300751400_jbmr3523-bib-0003","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrrheum.2014.188","article-title":"Glucocorticoid-induced osteoporosis: who to treat with what agent","volume":"11","author":"Rizzoli","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"2024021014300751400_jbmr3523-bib-0004","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int"},{"issue":"5","key":"2024021014300751400_jbmr3523-bib-0005","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2165\/00002018-200831050-00005","article-title":"Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis","volume":"31","author":"Etminan","year":"2008","journal-title":"Drug Saf"},{"issue":"11","key":"2024021014300751400_jbmr3523-bib-0006","doi-asserted-by":"crossref","first-page":"e008554","DOI":"10.1136\/bmjopen-2015-008554","article-title":"Bone mineral density and fracture risk with long-term use of inhaled corticosteroids in patients with asthma: systematic review and meta-analysis","volume":"5","author":"Loke","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"2024021014300751400_jbmr3523-bib-0007","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1164\/rccm.200305-640OC","article-title":"Inhaled and nasal corticosteroid use and the risk of fracture","volume":"169","author":"Suissa","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2024021014300751400_jbmr3523-bib-0008","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2796.2005.01467.x","article-title":"Fracture risk associated with systemic and topical corticosteroids","volume":"257","author":"Vestergaard","year":"2005","journal-title":"J Intern Med"},{"issue":"6","key":"2024021014300751400_jbmr3523-bib-0009","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"van Staa","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2024021014300751400_jbmr3523-bib-0010","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses","volume":"39","author":"van Staa","year":"2000","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"2024021014300751400_jbmr3523-bib-0011","article-title":"The design and validation of a new algorithm to identify initial and recurrent incident fragility fractures in administrative claims data","volume":"33","author":"Wright","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024021014300751400_jbmr3523-bib-0012","first-page":"69","article-title":"Identification and validation of vertebral compression fractures using administrative claims data","volume":"47","author":"Curtis","journal-title":"Med Care. 2009"},{"issue":"7","key":"2024021014300751400_jbmr3523-bib-0013","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0895-4356(92)90047-Q","article-title":"Identification of fractures from computerized Medicare files","volume":"45","author":"Ray","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2024021014300751400_jbmr3523-bib-0014","first-page":"541","article-title":"Internal validation of Medicare claims data","volume":"5","author":"Baron","year":"1994","journal-title":"Epidemiology"},{"issue":"12","key":"2024021014300751400_jbmr3523-bib-0015","first-page":"700","article-title":"Interpreting estimates of treatment effects: implications for managed care","volume":"33","author":"Faraone","year":"2008","journal-title":"P T"},{"issue":"3","key":"2024021014300751400_jbmr3523-bib-0016","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2024021014300751400_jbmr3523-bib-0017","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024021014300751400_jbmr3523-bib-0018","year":"2009"},{"key":"2024021014300751400_jbmr3523-bib-0019","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"2024021014300751400_jbmr3523-bib-0020","first-page":"1055","article-title":"Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis","volume":"22","author":"Buckley","year":"1995","journal-title":"The J Rheumatol"},{"key":"2024021014300751400_jbmr3523-bib-0021","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11657-013-0169-5","article-title":"CaMos Research Group. Glucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre Osteoporosis Study (CaMos)","volume":"9","author":"Ioannidis","year":"2014","journal-title":"Arch Osteoporos"},{"issue":"4","key":"2024021014300751400_jbmr3523-bib-0022","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00198-013-2587-z","article-title":"Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom","volume":"25","author":"Bultink","year":"2014","journal-title":"Osteoporos Int"},{"issue":"4","key":"2024021014300751400_jbmr3523-bib-0023","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00198-015-3426-1","article-title":"Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort","volume":"27","author":"Bours","year":"2016","journal-title":"Osteoporos Int"},{"key":"2024021014300751400_jbmr3523-bib-0024","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bone.2018.02.007","article-title":"Use of high-dose intermittent systemic glucocorticoids and the risk of fracture in patients with chronic obstructive pulmonary disease","volume":"110","author":"Oshagbemi","year":"2018","journal-title":"Bone"},{"issue":"10","key":"2024021014300751400_jbmr3523-bib-0025","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s00198-017-4115-z","article-title":"Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis","volume":"28","author":"Oshagbemi","year":"2017","journal-title":"Osteoporos Int"},{"issue":"11","key":"2024021014300751400_jbmr3523-bib-0026","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1007\/s00198-016-3646-z","article-title":"Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis","volume":"27","author":"Balasubramanian","year":"2016","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024021014300751400_jbmr3523-bib-0027","first-page":"e486","article-title":"Osteoporosis management among chronic glucocorticoid users: a systematic review","volume":"21","author":"Albaum","year":"2014","journal-title":"J Popul Ther Clin Pharmacol"},{"issue":"8","key":"2024021014300751400_jbmr3523-bib-0028","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/art.21194","article-title":"Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients","volume":"52","author":"Curtis","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2024021014300751400_jbmr3523-bib-0029","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00198-010-1201-x","article-title":"An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis","volume":"22","author":"Caplan","year":"2011","journal-title":"Osteoporos Int"},{"issue":"4","key":"2024021014300751400_jbmr3523-bib-0030","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1210\/jc.2011-2645","article-title":"Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998\u20132008)","volume":"97","author":"Majumdar","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024021014300751400_jbmr3523-bib-0031","first-page":"1662","article-title":"CATCH Investigators","volume":"51","author":"McKeown","year":"2012","journal-title":"Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology"},{"issue":"9","key":"2024021014300751400_jbmr3523-bib-0032","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","article-title":"Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis","volume":"23","author":"Lekamwasam","year":"2012","journal-title":"Osteoporos Int"},{"issue":"9","key":"2024021014300751400_jbmr3523-bib-0033","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00198-008-0670-7","article-title":"Group for the Respect of Ethics and Excellence in Science. Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science","volume":"19","author":"Compston","year":"2008","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024021014300751400_jbmr3523-bib-0034","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","article-title":"Guidance for the adjustment of FRAX according to the dose of glucocorticoids","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int"},{"issue":"8","key":"2024021014300751400_jbmr3523-bib-0035","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.23279","article-title":"American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"2024021014300751400_jbmr3523-bib-0036","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00198-014-3022-9","article-title":"Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis","volume":"26","author":"Overman","year":"2015","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024021014300751400_jbmr3523-bib-0037","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bone.2013.05.009","article-title":"C-reactive protein and fracture risk: European prospective investigation into Cancer Norfolk Study","volume":"56","author":"Ahmadi-Abhari","year":"2013","journal-title":"Bone"},{"issue":"2","key":"2024021014300751400_jbmr3523-bib-0038","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jbmr.2037","article-title":"High-sensitivity CRP is an independent risk factor for all fractures and vertebral fractures in elderly men: the MrOS Sweden study","volume":"29","author":"Eriksson","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024021014300751400_jbmr3523-bib-0039","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/jbmr.1915","article-title":"C-reactive protein, bone strength, and nine-year fracture risk: data from the Study of Women's Health Across the Nation (SWAN)","volume":"28","author":"Ishii","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"22","key":"2024021014300751400_jbmr3523-bib-0040","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/archinte.166.22.2495","article-title":"High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study","volume":"166","author":"Schett","year":"2006","journal-title":"Arch Intern Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3523","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/10\/1881\/56650221\/jbmr3523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/10\/1881\/56650221\/jbmr3523.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:02:15Z","timestamp":1710327735000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/33\/10\/1881-1888\/7605296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,20]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,6,20]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3523","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10,1]]},"published":{"date-parts":[[2018,6,20]]},"assertion":[{"value":"2017-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}